

Survival and Prevalence Tables

Table P. 5-Year Relative Survival, 2010-2020, Louisiana

Primary Site ¹	All Races			NH White					NH Black		
	Total	Male	Female	Total	Male	Female			Total	Male	Female
All Sites	65.7%	65.5%	65.9%	67.4%	66.9%	↑	67.9%	↑	61.4%	62.1%	60.7%
Oral Cavity and Pharynx	62.6%	62.5%	62.8%	67.6%	68.2%	↑	66.0%	↑	45.0%	42.8%	50.8%
Lip	87.5%	87.9%	81.5%	87.7%	88.4%		80.3%		83.4%	80.4%	100.0%
Tongue	65.5%	65.5%	65.6%	70.4%	70.6%	↑	70.0%	↑	39.6%	37.9%	44.3%
Salivary Gland	72.5%	66.7%	81.5%	69.1%	64.4%		78.8%		79.7%	73.6%	84.2%
Floor of Mouth	47.2%	44.4%	52.8%	51.8%	48.0%	↑	58.0%	↑	35.3%	36.9%	24.6%
Gum and Other Mouth	56.1%	56.6%	55.4%	59.3%	60.4%		57.9%		48.7%	48.8%	47.9%
Nasopharynx	60.4%	58.5%	66.8%	60.3%	58.3%		65.7%		50.9%	51.0%	50.0%
Tonsil	72.0%	73.3%	65.1%	76.3%	77.4%	↑	69.6%	↑	52.6%	54.5%	42.4%
Oropharynx	46.3%	48.1%	40.9%	53.6%	57.2%	↑	44.4%		26.3%	23.7%	32.7%
Hypopharynx	31.3%	29.8%	38.1%	38.3%	36.9%	↑	43.6%		20.0%	18.3%	25.8%
Other Oral Cavity and Pharynx	44.8%	44.3%	46.2%	55.4%	57.5%	↑	46.8%		21.1%	13.4%	40.1%
Digestive System	44.0%	41.1%	47.7%	45.7%	43.0%	↑	49.3%	↑	40.9%	37.4%	45.3%
Esophagus	20.0%	17.8%	28.2%	21.7%	19.1%	↑	33.3%	↑	15.6%	13.9%	19.9%
Stomach	32.3%	29.3%	37.2%	34.6%	32.2%	↑	38.9%		29.8%	26.0%	35.4%
Small Intestine	72.0%	72.6%	71.1%	74.6%	72.7%		76.5%	↑	67.0%	70.2%	63.6%
Colon and Rectum	64.3%	63.4%	65.2%	66.2%	65.6%	↑	66.9%	↑	60.5%	58.8%	62.2%
Colon excluding Rectum	63.9%	63.8%	64.0%	66.2%	66.0%	↑	66.4%	↑	59.5%	59.2%	59.7%
Cecum	63.1%	64.1%	62.2%	65.9%	66.3%		65.6%	↑	58.1%	60.2%	56.5%
Appendix	79.4%	80.9%	78.0%	84.0%	87.9%	↑	81.1%	↑	63.2%	61.3%	64.9%
Ascending Colon	66.2%	63.2%	68.8%	67.8%	64.8%		70.6%		64.3%	62.1%	65.9%
Hepatic Flexure	63.8%	65.6%	61.7%	65.0%	66.1%		62.6%		62.5%	65.6%	58.2%
Transverse Colon	62.4%	60.2%	64.2%	63.7%	64.0%	↑	63.3%		59.0%	51.5%	65.4%
Splenic Flexure	63.9%	64.2%	62.9%	63.9%	62.7%		65.1%		64.0%	65.2%	61.4%
Descending Colon	64.1%	64.8%	63.0%	66.3%	68.0%		63.5%		60.1%	58.4%	61.1%
Sigmoid Colon	67.3%	67.8%	66.5%	69.6%	69.6%	↑	69.5%	↑	62.1%	63.0%	61.2%
Large Intestine, NOS	27.2%	29.0%	25.0%	26.3%	28.8%		23.2%		28.1%	28.0%	27.4%
Rectum and Rectosigmoid Junction	65.2%	62.9%	68.5%	66.2%	64.8%	↑	68.3%		63.1%	58.3%	69.4%
Rectosigmoid Junction	59.2%	57.5%	61.7%	61.9%	61.6%	↑	62.5%		52.8%	48.1%	58.9%
Rectum	66.8%	64.3%	70.3%	67.4%	65.7%	↑	69.9%		65.4%	60.5%	71.6%
Anus, Anal Canal and Anorectum	69.6%	63.6%	73.6%	72.6%	65.5%		76.5%		61.0%	57.6%	64.0%
Liver and Intrahepatic Bile Duct	16.9%	16.2%	19.0%	18.0%	17.3%	↑	20.2%		13.8%	13.4%	15.5%
Liver	18.0%	17.0%	21.6%	19.5%	18.3%	↑	24.0%		14.4%	13.9%	17.0%
Intrahepatic Bile Duct	6.2%	4.2%	8.0%	6.3%	5.1%	↑	7.0%		4.8%	4.1%	5.1%
Gallbladder	18.2%	14.2%	19.9%	17.9%	13.8%		19.6%		17.7%	17.7%	18.0%
Other Biliary	17.2%	15.3%	18.8%	17.7%	14.2%		21.3%		15.8%	16.0%	15.0%
Pancreas	8.8%	8.4%	9.2%	9.2%	8.9%	↑	9.5%		7.8%	6.7%	8.8%
Retroperitoneum	52.6%	45.5%	57.7%	52.1%	44.6%		59.4%		52.7%	37.5%	57.2%
Peritoneum, Omentum and Mesentery	26.8%	8.3%	28.7%	27.0%	11.9%		28.6%		22.2%	0.0%	25.1%
Other Digestive Organs	12.8%	11.5%	13.8%	9.7%	11.3%		7.6%		19.9%	12.5%	24.7%

Respiratory System	23.4%	22.1%	25.2%	23.9%	22.3%		25.9%		21.9%	21.2%	23.1%
Nose, Nasal Cavity and Middle Ear	62.2%	63.3%	60.5%	65.7%	67.0%		63.9%		47.9%	48.7%	44.8%
Larynx	57.7%	58.0%	56.3%	59.5%	59.5%	↑	59.0%		53.5%	54.0%	51.3%
Lung and Bronchus	20.0%	17.3%	23.5%	20.7%	17.7%		24.2%		18.3%	16.3%	21.2%
Pleura	20.2%	21.0%	20.2%	23.1%	23.3%		24.4%		0.0%	0.0%	0.0%
Trachea, Mediastinum and Other Respiratory	43.1%	46.0%	37.4%	45.5%	54.9%		33.3%		40.7%	40.3%	41.8%
Bones and Joints	64.3%	59.1%	69.6%	65.9%	57.0%		73.0%		58.7%	57.8%	59.9%
Soft Tissue including Heart	63.4%	64.4%	61.9%	66.6%	66.9%		66.0%	↑	56.4%	59.2%	53.5%
Skin excluding Basal and Squamous	92.5%	91.1%	94.4%	92.8%	91.5%	↑	94.8%		78.9%	71.0%	84.9%
Melanoma of the Skin	92.9%	91.7%	94.7%	93.4%	92.1%	↑	95.4%	↑	64.5%	55.8%	70.6%
Other Non-Epithelial Skin	88.1%	85.6%	90.9%	86.3%	84.9%		87.9%	↓	91.3%	83.0%	95.3%
Breast	88.3%	78.1%	88.4%	90.9%	80.6%		91.0%	↑	82.9%	73.1%	83.0%
Female Genital System	65.1%	--	65.1%	69.5%	--		69.5%	↑	55.8%	--	55.8%
Cervix Uteri	64.1%	--	64.1%	67.3%	--		67.3%	↑	57.8%	--	57.8%
Corpus and Uterus, NOS	74.9%	--	74.9%	82.2%	--		82.2%	↑	60.7%	--	60.7%
Corpus Uteri	76.8%	--	76.8%	83.5%	--		83.5%	↑	63.4%	--	63.4%
Uterus, NOS	20.3%	--	20.3%	23.8%	--		23.8%		14.0%	--	14.0%
Ovary	45.2%	--	45.2%	47.5%	--		47.5%	↑	38.7%	--	38.7%
Vagina	46.4%	--	46.4%	46.8%	--		46.8%		48.1%	--	48.1%
Vulva	72.3%	--	72.3%	73.5%	--		73.5%		67.6%	--	67.6%
Other Female Genital Organs	45.8%	--	45.8%	49.4%	--		49.4%		35.9%	--	35.9%
Male Genital System	99.5%	99.5%	--	99.8%	99.8%	↑	--		97.9%	97.9%	--
Prostate	99.8%	99.8%	--	99.9%	99.9%	↑	--		98.2%	98.2%	--
Testis	96.9%	96.9%	--	97.7%	97.7%	↑	--		89.9%	89.9%	--
Penis	66.3%	66.3%	--	69.9%	69.9%		--		56.3%	56.3%	--
Other Male Genital Organs	84.0%	84.0%	--	98.2%	98.2%	↑	--		54.9%	54.9%	--
Urinary System	76.3%	77.0%	74.9%	77.6%	78.1%	↑	76.4%	↑	71.8%	72.3%	71.1%
Urinary Bladder	77.9%	79.8%	71.9%	79.9%	80.9%	↑	76.4%	↑	67.3%	73.0%	55.6%
Kidney and Renal Pelvis	76.2%	75.2%	77.7%	76.7%	76.1%	↑	77.7%		75.0%	72.5%	78.3%
Ureter	45.8%	46.6%	44.3%	46.6%	47.3%		45.2%		34.5%	35.7%	35.4%
Other Urinary Organs	46.1%	54.6%	33.2%	49.0%	56.1%		33.6%		39.3%	49.3%	27.9%
Eye and Orbit	79.4%	80.3%	78.2%	78.7%	81.1%		75.7%		84.7%	74.9%	94.1%
Brain and Other Nervous System	32.8%	31.5%	34.4%	31.1%	29.9%		32.7%		35.0%	33.2%	37.1%
Brain	29.7%	29.0%	30.6%	28.4%	27.8%		29.1%		31.7%	30.9%	32.6%
Cranial Nerves Other Nervous System	78.8%	73.9%	83.8%	79.7%	72.5%		86.8%		73.0%	66.4%	76.6%
Endocrine System	97.4%	94.5%	98.2%	98.0%	95.6%	↑	98.7%	↑	95.0%	89.5%	96.2%
Thyroid	98.7%	97.1%	99.1%	99.0%	97.7%		99.4%	↑	97.7%	95.6%	97.9%
Other Endocrine including Thymus	66.3%	68.2%	63.9%	62.5%	64.0%		61.0%		69.2%	71.1%	66.9%
Lymphoma	72.6%	71.2%	74.3%	74.4%	73.5%	↑	75.3%	↑	67.2%	64.1%	70.7%
Hodgkin Lymphoma	85.2%	84.7%	85.7%	85.3%	85.7%		84.5%		85.4%	82.3%	88.9%
Hodgkin - Nodal	85.8%	85.5%	85.9%	85.9%	86.6%		84.8%		85.7%	82.9%	88.9%
Hodgkin - Extranodal	48.9%	44.0%	60.2%	43.7%	30.8%		60.2%		61.4%	61.4%	^
Non-Hodgkin Lymphoma	70.6%	69.0%	72.5%	72.8%	71.8%	↑	74.0%	↑	63.3%	59.9%	67.1%
NHL - Nodal	68.1%	66.0%	70.7%	70.6%	68.8%	↑	72.6%	↑	58.9%	56.4%	61.4%
NHL - Extranodal	75.5%	75.0%	75.7%	77.2%	77.6%	↑	76.5%		70.8%	66.3%	74.9%
Myeloma	55.7%	54.8%	56.8%	55.6%	56.0%		55.0%		55.3%	52.2%	58.2%

Leukemia	64.6%	63.8%	65.6%	66.3%	64.9%	↑	68.0%	↑	58.7%	59.7%	57.6%
Lymphocytic Leukemia	84.0%	82.3%	86.4%	85.6%	83.7%	↑	88.3%	↑	76.7%	76.6%	76.9%
Acute Lymphocytic Leukemia	69.5%	67.6%	71.6%	71.1%	70.5%		71.6%		62.9%	59.7%	67.2%
Chronic Lymphocytic Leukemia	88.1%	86.1%	90.9%	89.0%	86.6%		92.5%	↑	82.0%	82.7%	81.1%
Other Lymphocytic Leukemia	81.1%	79.0%	83.9%	83.8%	80.9%		89.4%		66.0%	67.3%	59.7%
Myeloid and Monocytic Leukemia	41.5%	39.4%	43.9%	40.6%	38.0%		43.7%		43.2%	41.4%	45.0%
Acute Myeloid Leukemia	25.8%	23.7%	28.1%	24.0%	20.9%		27.7%		29.3%	29.2%	29.4%
Acute Monocytic Leukemia	21.9%	26.7%	14.6%	21.2%	28.7%		12.0%		22.9%	16.8%	25.7%
Chronic Myeloid Leukemia	67.7%	65.2%	70.7%	67.1%	64.6%		70.0%		68.4%	64.2%	72.8%
Other Myeloid/Monocytic Leukemia	32.4%	23.6%	45.1%	30.6%	29.4%		36.1%		22.7%	0.0%	67.8%
Other Leukemia	55.8%	58.9%	52.0%	54.7%	56.6%		51.8%		57.0%	59.5%	52.8%
Other Acute Leukemia	28.9%	22.1%	37.0%	27.0%	19.4%		35.7%		26.5%	^	40.6%
Aleukemic, Subleukemic and NOS	67.1%	73.8%	58.0%	66.2%	71.7%		58.9%		69.2%	80.1%	55.8%
Mesothelioma	9.3%	6.2%	16.6%	9.8%	7.3%		15.5%		7.0%	0.0%	20.9%
Kaposi Sarcoma	70.2%	70.7%	60.4%	87.8%	87.6%	↑	83.0%		55.5%	57.3%	^
Miscellaneous	39.2%	37.6%	40.9%	41.2%	40.6%	↑	42.0%	↑	33.5%	28.9%	37.7%

¹Except for urinary bladder (in situ and invasive), only invasive cases are included.

^The statistic could not be calculated.

↑ or ↓ Within Louisiana, white sex-specific relative survival is significantly (p < 0.05) higher or lower than black sex-specific relative survival.

--Not applicable.

Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2021^{1,2}

Site/Region	Louisiana	New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Sites	197,564	37,120	41,326	29,343	27,460	12,553	12,298	23,678	14,247
Oral Cavity and Pharynx	5,200	893	1,085	805	726	341	355	618	383
Esophagus	729	118	158	104	95	55	52	100	46
Stomach	1,575	355	322	219	221	84	114	177	84
Colon and Rectum	19,528	3,487	3,825	2,633	2,984	1,278	1,381	2,404	1,542
Liver and Intrahepatic Bile Duct	1,483	439	293	234	169	83	46	154	65
Pancreas	1,245	261	241	218	171	61	70	148	77
Larynx	1,997	369	402	294	301	128	116	253	132
Lung and Bronchus	9,128	1,801	1,754	1,331	1,375	586	587	1,025	677
Melanoma of the Skin	9,831	1,501	2,398	1,657	1,098	678	601	1,055	850
Breast ³	40,963	8,392	8,389	6,147	5,780	2,394	2,160	4,831	2,919
Cervix Uteri	2,444	484	455	302	352	177	161	338	176
Corpus and Uterus, NOS	6,208	1,181	1,184	844	870	398	406	849	476
Ovary	1,781	355	393	298	221	111	108	191	103
Prostate	46,538	8,544	10,679	6,218	6,382	2,920	2,786	5,740	3,267
Testis	1,818	341	385	269	254	138	128	190	115
Urinary Bladder ⁴	8,090	1,486	1,608	1,404	1,085	531	550	940	492
Kidney and Renal Pelvis	10,588	1,882	2,202	1,669	1,579	693	667	1,165	740
Brain and Other Nervous System	1,488	275	311	242	207	92	103	163	95
Thyroid	9,214	1,556	1,707	1,448	1,396	601	660	1,119	728
Hodgkin Lymphoma	1,933	369	372	310	264	127	139	227	125
Non-Hodgkin Lymphoma	8,632	1,694	1,706	1,392	1,174	610	530	981	545
Myeloma	2,558	530	578	371	282	135	131	346	186
Leukemia	5,379	847	1,055	858	760	395	364	688	412
Acute Lymphocytic Leukemia	783	135	174	123	109	56	45	86	55
Mesothelioma	115	28	26	23	13	11	^	^	7
Kaposi Sarcoma	217	95	48	15	20	8	^	18	9

¹ January 1, 2021, 21-Year Limited Duration Prevalence counts are based on 2021 cancer prevalence proportions from SEER 17 registries. Populations were estimated by averaging 2020 and 2021 populations.

²Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 21 years (2000-2020). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 21 years (2000-2020).

³ Breast tumor includes both sexes. ⁴ Urinary bladder category includes urinary bladder tumor in situ. ^Statistic not displayed due to fewer than 6 prevalent cases.

Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers
Only, January 1, 2021^{1,2}

Site/Ages	All ages	0-19	20-39	40-49	50-59	60-69	70-79	80-89
All Sites	197,564	3,411	15,353	24,368	51,734	65,082	36,025	9,683
Oral Cavity and Pharynx	5,200	47	292	736	1,678	1,595	723	221
Esophagus	729	^	11	60	180	273	164	42
Stomach	1,575	^	78	167	389	513	338	92
Colon and Rectum	19,528	52	874	2,231	5,675	6,099	3,573	1,170
Liver and Intrahepatic Bile Duct	1,483	44	25	62	415	633	254	53
Pancreas	1,245	6	62	102	274	425	293	85
Larynx	1,997	^	45	226	617	714	320	80
Lung and Bronchus	9,128	9	128	441	1,908	3,442	2,597	766
Melanoma of the Skin	9,831	110	1,446	1,553	2,288	2,383	1,598	595
Breast ³	40,963	^	2,515	7,415	11,292	11,934	6,663	2,019
Cervix Uteri	2,444	^	907	685	480	263	79	29
Corpus and Uterus, NOS	6,208	^	403	834	1,870	2,082	849	167
Ovary	1,781	52	258	291	455	422	224	78
Prostate	46,538	^	40	1,662	12,151	21,377	9,921	1,386
Testis	1,818	95	1,163	362	157	34	^	^
Urinary Bladder ⁴	8,090	8	168	505	1,644	2,735	2,266	820
Kidney and Renal Pelvis	10,588	178	588	1,466	2,839	3,348	1,848	420
Brain and Other Nervous System	1,488	541	398	203	163	119	61	11
Thyroid	9,214	167	2,392	2,020	2,190	1,649	681	121
Hodgkin Lymphoma	1,933	275	942	280	225	133	58	20
Non-Hodgkin Lymphoma	8,632	247	876	979	1,942	2,439	1,703	528
Myeloma	2,558	^	63	241	576	885	594	201
Leukemia	5,379	790	474	519	1,010	1,304	918	368
Acute Lymphocytic Leukemia	783	614	71	25	39	23	9	^
Mesothelioma	115	^	13	13	20	28	27	11
Kaposi Sarcoma	217	^	98	46	29	17	16	12

¹ January 1, 2021, 21-Year Limited Duration Prevalence. Populations were estimated by averaging 2020 and 2021 populations.

² Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 21 years (2000-2020). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 21 years (2000-2020).

³ Breast tumor includes both sexes.

⁴ Urinary bladder category includes urinary bladder tumor in situ.

^Statistic not displayed due to fewer than 6 prevalent cases.

Other Tables

Table S. Percent of Cases^{1,2} with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2017-2021, Louisiana

	Microscopically Confirmed	All Cases	Percent Microscopically Confirmed
All Sites	126,158	134,253	94.0%
Oral Cavity and Pharynx	3,649	3,708	98.4%
Esophagus	1,230	1,267	97.1%
Stomach	1,874	1,920	97.6%
Small Intestine	906	919	98.6%
Colon and Rectum	11,784	12,096	97.4%
Colon excluding Rectum	8,150	8,410	96.9%
Rectum and Rectosigmoid Junction	3,634	3,686	98.6%
Liver	1,480	2,763	53.6%
Pancreas	3,511	4,064	86.4%
Larynx	1,390	1,407	98.8%
Lung and Bronchus	15,787	17,610	89.6%
Melanoma of the Skin	4,779	4,791	99.7%
Breast	18,548	18,717	99.1%
Corpus and Uterus, NOS	3,168	3,216	98.5%
Ovary	1,157	1,232	93.9%
Prostate	19,493	19,832	98.3%
Urinary Bladder	4,930	5,001	98.6%
Kidney and Renal Pelvis	5,837	6,424	90.9%
Brain and Other Nervous System	1,283	1,470	87.3%
Thyroid	3,231	3,246	99.5%
Hodgkin Lymphoma	651	657	99.1%
Non-Hodgkin Lymphoma	4,967	5,095	97.5%
Myeloma	1,925	2,321	82.9%
Leukemia	3,447	3,733	92.3%
Mesothelioma	277	290	95.5%
Kaposi Sarcoma	110	115	95.7%

¹Case counts represent the total combined number of cases for the 5-year period.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.